LIR-7 Activators
LIR-7 Activators encompass a diverse array of chemical compounds that indirectly enhance the functional activity of LIR-7 through their influence on various signaling pathways and cellular processes. Forskolin stands out by increasing cAMP levels, thereby activating PKA, which can phosphorylate components of the LIR-7 signaling cascade, leading to its functional enhancement. Sphingosine-1-phosphate and Thapsigargin both exert their effects through the modulation of lipid signaling and intracellular calcium levels respectively, potentially intensifying the signaling events that LIR-7 participates in. PMA, through the activation of PKC, modulates phosphorylation patterns within the LIR-7 signaling network, resulting in the fortification of LIR-7's role. Additionally, kinase inhibitors such as Epigallocatechin gallate and thePI3K inhibitors LY294002 and Wortmannin may repress negative regulatory kinases, thereby fostering an environment conducive to LIR-7 activation.
Compounds like SB203580 and U0126, which target the MAPK signaling components p38 and MEK1/2, respectively, can recalibrate intracellular signaling dynamics to bolster pathways that activate LIR-7. A23187, by augmenting intracellular calcium, and Staurosporine, despite its broad kinase inhibitory properties, have the potential to selectively lift the suppression of LIR-7-associated processes, amplifying LIR-7's functional activity. Zoledronic acid, through its impact on the mevalonate pathway and small GTPase function, further substantiates the activation of LIR-7 by influencing the signaling milieu in which LIR-7 operates. Collectively, these LIR-7 Activators, by targeting distinct cellular processes and signaling intermediates, orchestrate a symphony of biochemical events that culminate in the heightened activity of LIR-7, without necessitating a direct increase in its expression levels or direct activation of the protein itself.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
Sphingosine-1-phosphate functions as a signaling lipid that activates G protein-coupled receptors, potentially leading to downstream effects that enhance the signaling cascade in which LIR-7 is involved, thus indirectly increasing the functional activity of LIR-7. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin inhibits the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA), leading to an increase in cytosolic calcium levels. Elevated intracellular calcium can activate calcium-dependent kinases or enzymes that could influence the signaling pathways involving LIR-7, thereby enhancing its activity. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA acts as a potent protein kinase C (PKC) activator, which can modulate multiple signaling pathways. PKC activation could lead to altered phosphorylation states of proteins within the LIR-7 signaling pathway, culminating in increased LIR-7 activity. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is a kinase inhibitor that may reduce the activity of kinases that negatively regulate pathways in which LIR-7 operates. This reduction in inhibitory kinase activity could lead to enhanced functioning of the LIR-7 protein. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that modifies PI3K/AKT signaling. By inhibiting this pathway, LY294002 may shift the balance of cellular signaling towards pathways that upregulate or activate LIR-7, thus enhancing its activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor with a mechanism of action similar to LY294002. It could also shift cellular signaling in favor of pathways that enhance LIR-7 activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that could influence the cellular signaling landscape by reducing p38 MAPK activity, possibly resulting in the augmentation of signaling pathways that activate LIR-7. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 inhibits MEK1/2, which are upstream of ERK in the MAPK pathway. Inhibition of MEK could lead to altered cellular responses that enhance the signaling pathways involving LIR-7. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 is an ionophore that increases intracellular calcium levels. This elevation in calcium can activate pathways that enhance the activity of LIR-7 through calcium-dependent signaling mechanisms. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a broad-spectrum protein kinase inhibitor that may preferentially inhibit kinases that suppress LIR-7 activity, thus serving to enhance LIR-7 function. | ||||||